Mabylon AG
Swiss biotech company in immunology and inflammation (I&I). Our lead assets are in the allergy space, the fastest growing Type 2 immunology market with major unmet medical need.
We are currently raising our series B (USD 60M). 1/3 of the 60M series B has been already committed by current investors.
Phase 1 for our lead asset (antibody for peanut allergy) is expected to start in Q4 2025.
• 100% protection
• fewer injections/year (2 injections/year)
• rapid onset of immunity
Date, time and room information
May 5, 15:45 - 16:00, room Singapore
Category
Emerging biotech company
Title of the presentation
MABYLON AG, A RADICALLY NOVEL APPROACH TO TREAT ALLERGIES: ALLERGEN NEUTRALIZATION
Speaker information
| Name | Position | Institution |
|---|---|---|
| Alcide Barberis | CEO | Mabyon AG |
